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ABSTRACT 
The first reversed phase high performance liquid chromatographic method for Stability Indicating of, Azilsartan and chlorthalidone has been 
developed and validated to be a simple, sensitive, rapid, specific, precise, and accurate method. Chromatographic separation was achieved on 
Zorbax XBD-C8, 250mm × 4.6mm,5µm.Buffer pH5.5 : Methanol  (60:40) as a mobile phase at flow rate of 1 ml/min. UV detection was operated 
at 234 nm and injection volum was 25 μl.. The proposed method showed good linearity, accuracy, precision and was successfully applied for 
determination of the drugs in laboratory prepared pharmaceutical dosage forms. 
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INTRODUCTION: 
Azilsartan Medoximil[1] : 
Azilsartan is used in the treatment of hypertention. It is a 
angiotensin II receptor antagonist. Its mechanism of action is 
blocking the angiotensin receptor by vasopressor harmone 
that stops vasoconstriction and thus decreases the blood 
pressure. Its IUPAC name is (5-methyl-2-oxo-1,3-dioxol-4-
yl)methyl2- ethoxy-1-([2'-(5-oxo-4,5-dihydro-1,2,4-
oxadiazol-3- yl)biphenyl-4-yl]methyl)-1H-benzimidazole-7- 
carboxylate and molecular formula C30H23KN4O8.Azilsartan 
was practicaly insoluble in water but soluble in DMSO and 
methanol. Pka of the drug was 
 
Fig. 1 Structure of Azilsartan Medoxomil 
 
Pharmacokinetics: Azilsartan medoxomil is quickly absorbed 
from the gut, independently of food intake. Maximal blood 
plasma concentrations are reached after one to three hours. 
The liver enzyme CYP2C9 is involved in the formation of the 
two main metabolites, which are pharmacologically inactive; 
they are the O-deethylationand decarboxylation products of 
azilsartan. 
Adverse Drug Reaction: nausea,diarrhea,fatigue,cough.  
Chlorthlidone : 
. Chlorthalidone is used in the treatment of hypertension, it 
is a thiazide diuretic drug which inhibits Na+ and Cl- ions re-
absorption in the distal convoluted tubule by blocking the 
Na+ /Cl-Symporter. IUPAC name was (RS)-2-Chloro-5-(1- 
hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzene-1-
sulfonamide with molecular formula C14H11ClN2O4S. 
Chlorthalidone was soluble in Methanol, water and DMSO. 
Pka found was 8.76. According to literature two methods 
were available in which madhu et al., the retention time for 
Chlortalidone and AzilsartanMedoxomil were 7min and 11 
min respectively. Naazneen et al., the retention time for 
Chlortalidone and AzilsartanMedoxomil were 2.36±0.1 mins 
and 5.54±0.5 minsrespectively. 
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 Fig. 2 Structure of Chlorthalidone 
Pharmacokinetics: Chlortalidone is slowly absorbed from 
the gastrointestinal tract after oral ingestion. It has a long 
half-life and therefore a prolonged diuretic action, which 
results in continued diuretic effects despite a skipped dose. 
This prolonged action of chlortalidone despite missing doses 
may account for the higher efficacy of chlortalidone 
compared to the shorter half-life medication, 
hydrochlorothiazide. Chlortalidone is eliminated from the 
body mostly by the kidney, as unchanged drug.[2] 
Adverse Drug 
Reaction:Hyperuricemia,Hyperglycemia,Hyperlipidemia 
MATERIAL:  
 DRUG: 
Table 1: Drug and drug product samples suppliers and 
manufacturers 
Name of drug and drug 
product 
Supplier and 
manufacturer by 
Chlorthalidone Amoli organics pvt 
ltd,mumbai 
Azilsartan Medoxomil Honour lab limted 
hydrabad  
Chlorthalidone and Azilsartan 
Medoxomil Tablet 
Ipca pharmaceutical pvt 
ltd,Gujrat 
 
 REAGENTS: 
Table 2: List of Reagent[3] 
Sr.No Chemical Make 
1 Water Rankem 
2 Acetonitrile Merck life science 
3 Phosphoric acid 88% Merck life science 
4 Potassium dihydrogen 
phosphate 
Merck life science 
5 Sodium hydroxide Merck life science 
6 Triethylamine Merck life science 
7 0.45 µ Nylon membrane 
disc filter 
Mdi 
8 0.45μ PVDF Syringe Filter Mdi 
INSTRUMENTS: 
Table No 3: HPLC 
Make Waters e2695 
Pump Reciprocating Water-510 
Detector Waters 2695 PDA 
Software Empower PRO 
Column X-Bridge 
 
 
SPECTROPHOTOMETER: Double beam UV-visible 
spectrophotometer with 10mm Matched quartz cells 
Model UV1700 
Make Thermo scientific 
 
 ANALYTICAL BALANCE: Digital Analytical balance 
Model XS205D0 
Make Mettler Toledo 
 
 PH METER: Digital pH Meter 
Make  Thermo Scientific 
Model Orian Star A211 
 
 METHOD 
 UV SPECTROSCOPIC2 SELECTION OF WAVELENGTH 
Preparation of Chlorthalidone Standard solution: An 
accurately weighed quantity about 15 mg of Chlorthalidone 
standard was transferred to 200 mL volumetric flask. Add 
150 mL of diluent, sonicate to dissolve and dilute up to the 
mark with diluent and mixed. 
Preparation of Azilsartan Medoxomil Standard solution: 
An accurately weighed quantity about 20 mg of Azilsartan 
Medoxomil standard was transferred to 100 mL volumetric 
flask. Add 70 mL of diluent, sonicate to dissolve and dilute 
up to the mark with diluent and mixed. 
Preparation of Chlorthalidone Standard stock solution: 
Weigh accurately about 50 mg of Chlorthalidone and 
transfer it into 50 mL amber colored volumetric flask. Add 
about 30 mL of diluent, sonicate to dissolve and make up to 
mark with diluent (1.0mg/mL). 
Preparation of Azilsartan Medoxomil Standard stock 
solution: Weigh accurately about 80 mg of Azilsartan 
Medoxomil working standard and transfer it into 50 mL 
amber colored volumetric flask. Add about 30 mL of diluent, 
sonicate to dissolve and make up to mark with diluent (1.6 
mg/mL ppm). 
Further dilute 5 mL each of Chlorthalidone stock solution 
and Azilsartan Medoxomil Standard stock solution to 50 mL 
with diluent. (0.10 mg/mL Chlorthalidone and 0.16 mg/mL 
of Azilsartan Medoxomil). 
Note: Prepare standard solution in duplicate as 1st standard 
solution and 2nd standard solution. 
Preparation of Sample solution: 
Chlorthalidone and Azilsartan Medoxomil) stock 
solution: 
Weigh and transfer 10 tablets into 1000 mL amber colored 
volumetric flask. Add about 100 mL of water and sonicate to 
disperse the tablets then add 600 mL of diluent, sonicate for 
about 60 minutes along with intermittent shaking for 
complete disintegration of tablets. Allow it to cool and make 
up to volume with diluent. Centrifuge the solution for about 
10 minutes at 3000 rpm. Filter through 0.45µ Nylon 
membrane syringe filter. Inject stock solution for 
Chlorthalidone (0.1 mg/mL of Amlodipine).Further dilute 5 
mL of sample stock solution to 50 mL with diluent (0.16 
mg/mL of Azilsartan Medoxomil).[2] 
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Selection of Wavelength:
 
Fig 3 Spectra showing λ max of Chlorthalidone & Azilsartan Medoxomil 
Optimized Chromatographic  Condition: 
Column : Zorbax XBD-C8, 250 mm  x 4.6 mm, 5µm or equivalent 
Part No.990967-906 
Mobile Phase  Buffer pH5.5::methanol (60:40/v) 
Flow Rate : 1.0 mL/min  
Injection Volume : 25 µL 
Wavelength : 234 nm 
 
 
           Fig. 4 Typical  Optimised chromatogram Azilsartan Medoxomil, Chlorthalidone 
Result and Discussion – 
Table 3: Result of linearity. 
Conc.of Chlorthalidone 
HCL( conc in ppm ) 
Area Conc. of AzilsartanMedoxomil. (conc 
in ppm) 
Area 
50.56 1245690 80.010 1593708 
76.8 1875783 121.615 2419267 
101.12 2470595 160.020 3184787 
127.41 3200029 201.625 4069226 
151.68 3819248 240.030 4857134 
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Fig.No. 5.Linearity graph for Chlorthalidone HCL. 
 
Fig.No 6.Linearity graph for AzilsartanMedoxomil.
Table 4: % Recovery data for Chlorthalidone HCL and AzilsartanMedoxomil 
Drug % Composition % Recovery % mean RSD 
 
Chlorthalidone HCL 
50 100.4 99.60 
100 98.01 
150 100.02 
 
Azilsartan Medoxomil. 
50 100.00 99.90 
100 100.5 
150 99.01 
 
  Robustness:  
Table 5 Robustness for Chlorthalidone 
Changes in 
parameters 
Values Retention  Time of 
Chlorthalidonepeak 
Symmetry 
Factor  
Theoretical 
plates 
% RSD of 
standard 
area 
% 
Assay 
Absolute 
difference 
Control As per 
method 
6.757 1.17 10536 0.41 100.7 - 
Flow rate 
(± 0.1 mL/min) 
+0.1 
mL/min 
6.030 1.17 8824 0.65  
99.9 
0.6 
-0.1 
mL/min 
7.304 1.18 12176 0.12 100.0 0.7 
Change in 
Wavelength 
(± 5 nm) 
+5 nm   6.880 1.21 11758 0.20 100.3 0.4 
-5 nm 6.880 1.22 11770 0.21 100.6 0.1 
Change in Column 
temperature  
(± 5°C) 
+5°C 6.147 1.17 9259 0.12 98.9 1.8 
-5°C 6.404 1.18 9809 0.46 99.8 0.9 
       
 
Table 6 Robustness for Azilsartan Medoxomil 
Changes in 
parameters 
Values Retention  Time of 
AzilsartanMedoxomil 
peak 
Symmetry 
Factor 
Theoretical 
plates 
% RSD of 
standard 
area 
% 
Assay 
Absolute 
difference 
Control As per 
method 
11.801 1.08 36432 0.32 100.9 - 
Flow rate 
(± 0.1 mL/min) 
+0.1 
mL/min 
10.997 1.08 33021 0.29 100.4 0.5 
-0.1 
mL/min 
12.433 1.09 40650 0.04 101.6 0.7 
Change in 
Wavelength (± 5 
nm) 
+5 nm 11.638 1.11 37461 0.13 100.9 0.0 
-5 nm 11.638 1.11 37491 0.18 100.4 0.5 
Change in 
Column 
temperature  
(± 5°C) 
+5°C 11.195 1.08 35529 0.09 100.0 0.9 
-5°C 11.473 1.09 36018 0.37 101.6 0.3 
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CONCLUSION 
The proposed simultaneous eatimation and validation method was 
found to be simple, precise, accurate and rapid  for the 
determination  of Chlorthalidone and AzilsartanMedoxomil.The 
coefficient of correlation was obtained in acceptable range .The 
percentage recovery obtained in acceptable range .variation in flow 
rate, wavelength, does not have any effect on the % RSD of standard 
and assay value.There lative standard deviation of main peak area 
,tailing factor and therotical plate  is well within the acceptable 
range . Hence the precision of given method is confirmed. Thus from 
the above result of the individual method is conclude that the 
analytical method is validated and found to be satisfactory. 
ACKNOWLEDGMENT 
The authors express their gratitude to the Pravara Rural College of 
Pharmacy,Loni  and a division of Amoli lab Limited,Mumbai and 
Honour limted Hydrabad  for providing the gift sample of Azisartan 
medoximil and Chlorthalidone. 
REFERENCES 
1. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors 
as a new treatment for diabetes mellitus. J 
ClinEndocrinolMetab, (2010); 5(1), page no:34-42. 
2. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S, 
et al. Effect ofdapagliflozin in patients with   type 2 diabetes 
who have inadequate glycaemic control withglimepiride: a 
randomized, 24-week, double- blind, placebo-controlled trial. 
DiabetesObesMetab,(2011); 13(10):page no : 928-938. 
3. Kim Y, Babu AR. Clinicalotential of sodium- glucose 
cotransporter 2 inhibitors in the management of type 2 
diabetes. Diabetes MetabSyndrObes, (2012); 5(3),page no 
:313-327. 
4. Janssen Research & Development, LLC. Canagliflozin as an 
adjunctive treatment to diet and exercise alone or 
coadministered with other antihyperglycemic agents to 
improve glycemic control in adults with type 2 diabetes 
mellitus ,(2013), page no :224-231. 
5. http://www.mediclnewstoday.com 
6. http://www.thediabeticvoice.com 
7. Cindy Green, RAC. A Step By Step Approach to Establishing a 
Method Validation. Journal of Validation Technology August 
2007; 13(4):p.317-323 
8. Vasant D. Khasia, Hetal V. Khasia, Dhara Desai, Dharmishtha N. 
Bhakhar, Ashok R. Parmar, “Development and  Validation of 
Stability Indicating RP-HPLC Method for Immediate Release 
Tablet Dosage Form”, Journal of Pharmacy research, 2012, 
5(8),4115-4118.
 
 
 
 
